Celltrion Launches Higher-Strength Yuflyma Adalimumab In Canada
Public And Private Listings For Reimbursement Are In The Works
Months after it received approval from local regulator Health Canada, Celltrion’s Yuflyma high-concentration adalimumab biosimilar is now available in the North American market, setting up a potential rivalry with Alvotech and its marketing partner JAMP Pharma.
